Jumpcan pharmaceutical adjusts incentives, repurchases shares, and initiates vesting

Hubei Jumpcan Pharmaceutical announced the cancellation of 171,800 stock options and the repurchase and cancellation of 171,800 restricted shares. This action, approved by the board on September 9, 2025, stems from the departure of three incentive recipients and the failure of five incentive recipients to meet 2022 performance targets, leading to a reduction in registered capital by 171,800 yuan. The repurchase price for restricted shares is 16.00 yuan per share plus the interest on a fixed deposit at the People's Bank of China for the same period.

Concurrently, the company announced the first vesting period for its 2022 restricted stock and stock option incentive plan. Of the initial grant, 58 incentive recipients are eligible to unlock 1,630,800 restricted shares, and 60 incentive recipients can exercise 1,714,800 stock options. The exercise price for stock options has been adjusted to 20.74 yuan per share (after dividend adjustments, including 2022-2024 cash dividends of 0.88 yuan, 1.30 yuan, and 2.08 yuan per share, respectively), a reduction from the initial 25.00 yuan.

The company's board believes these adjustments align with regulatory requirements and do not negatively impact financial health or shareholder interests. These steps streamline the incentive plan by removing ineligible participants and adjusting option pricing to reflect dividend distributions.